Zdrowie i gospodarka · 29/09/2025
FDA Clears SEMPREX-D Capsules for Approval
The FDA has determined that SEMPREX-D capsules, 8mg and 60mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of acrivastine and pseudoephedrine hydrochloride capsules.